iCarbonX integrates multi-omics technologies, such as genomics, proteomics, metabolomics, microbiome and phenotypical profiling, into our Digital Life Platform. Since 2019, we shifted our focus to revolutionize research for innovative biomarker discoveries, thereby facilitating the work of our partners to advance their translational endeavors from basic science to clinical diagnostics.
Fighting Cancers with iCarbonX Tools
According to the International Agency for Research on Cancer (IARC), in 2020 doctors newly diagnosed up to 4.5 million patients suffering from various cancers in China; three million people died from their disease. As with other diseases, cancer afflicts humankind without regard to geography: Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.【1】
Cancer thus is one of the most critical global public health issues, calling urgently for progress in the availability and accuracy of early screening and diagnosis to enable early intervention. For example, advances in early screening technologies would provide real benefits in China and other developing countries where a significantly higher proportion of cancer patients are diagnosed at later stages of tumor progression , compared to developed countries.
Our Digital Life Platform helps clinical doctors to comprehensively profile cancer patients and to cross-validate biomedical markers between multiple molecular levels in order to distinguish truly meaningful markers from spurious signals. For example, lung cancer was the leading cause of cancer deaths worldwide in 2020.【2】 If lung cancer is found while it remains small and before it has spread, successful treatment is more likely.【3】According to the U.S. Center for Disease Control, the only recommended screening test for lung cancer is low-dose computed tomography (LDCT).【4】
Using the integrative biomarkers identified on our Digital Life Platform in conjunction with LDCT screening, leading research hospitals have been able to profile their longitudinal cohorts and to distinguish malignant early lung nodules at an unprecedented 89%-91% accuracy rate.
Fighting Chronic Disorders with iCarbonX Tools
Chronic non-infectious disorders are highly prevalent and life-threatening around the world, imposing a heavy burden on public resources. According to the World Bank, common disorders such as hypertension, cardiovascular diseases, and diabetes accounted for nearly 90% of deaths in China and 74% of deaths globally in recent years.【5】Early screening, preventive intervention, prognosis tracking, and precision medicine are keys to reducing health impacts of chronic diseases on people and the consequential burdens on public welfare.
Our Digital Life Platform helps clinical researchers and doctors to understand the complications of chronic disorders and to position their patients for effective treatment through precision medicine.For example, an estimated 5%-10% of 463 million adult diabetes patients were mis-diagnosed as having type 2 instead of type 1, and hence mis-treated until further symptoms developed.
One cause of mis-diagnosis is latent autoimmune diabetes in adults (LADA), which presents similarly to T2D. Employing novel biomarkers discovered with the Digital Life Platform now enables doctors to more accurately diagnose rare subtypes of diabetes in their initial encounters with patients.
Fighting Infectious Diseases with iCarbonX Tools
The COVID-19 pandemic brings particular focus of public health efforts to infectious diseases caused by bacteria and viruses. Nearly 200 million COVID-19 cases have been reported worldwide, with over 4 million deaths. Infections or vaccinations can stimulate neutralizing COVID-19 antibody synthesis in the body and constitute an immune barrier against future infection.
Accurate assessment of neutralizing antibody levels would more precisely evaluate one’s vulnerability and the effectiveness of a treatment plan. It could also serve for efficacy evaluation in development of vaccines and therapeutics. iCarbonX is working with vaccination researchers to achieve to measure neutralizing antibody levels with ever-increasing accuracy.
Leading vaccine company achieve 50% increase in neutralizing antibody responses due to the sensitivity of discovery on our Digital Life Platform.
Our Partners Served by Digital Life Platform
iCarbonX is proud to collaborate with leading health research institutions
and providers around the world.

Have a question about iCarbonX Digital Life Platform?

Please email to We will reply as soon as possible.